Mirabegron: A new option in treating overactive bladder.
Antimuscarinic medications have long been the mainstay of drug treatment for overactive bladder. This article describes mirabegron, one of a new class of agents that relaxes the detrusor muscle directly via a beta3 adrenoceptor agonist. Mirabegron's efficacy on frequency, urgency, and urge incontinence was tested in several trials before its wide clinical introduction. However, caution is still needed as data are lacking on the drug's efficacy and safety in frail older adults and for long-term therapy.
Heidi Camus Turpen practices at the University of Texas Southwestern Medical Center in Dallas, Tex. Philippe E. Zimmern is a professor of urology at the University of Texas Southwestern Medical Center. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Heidi Camus
HC
Turpen
Philippe E
PE
Zimmern
D000083:Acetanilides / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D065690:Cytochrome P-450 CYP2D6 Inhibitors / Q000009:adverse effects; D004347:Drug Interactions; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D018727:Muscarinic Antagonists; D013844:Thiazoles; C520025:mirabegron